Semaglutide 2.4 mg: Wegovy's FDA-Approved Max Dose (Target Maintenance)
The FDA-approved 2.4 mg weekly dose is the target endpoint of Wegovy titration — 15% mean body weight reduction in STEP 1, achievable at week 17+ after standard escalation.
Semaglutide 2.4 mg weekly is the FDA-approved maximum dose for chronic weight management (Wegovy). It's where the famous STEP 1 NEJM 2021 trial measured its 14.9% mean body-weight reduction; it's where most published Wegovy outcomes come from; and it's the target endpoint of the standard 16-week titration. Patients reach 2.4 mg at week 17 and typically maintain it for the duration of treatment.
What 2.4 mg produces
STEP 1 (Wilding et al, NEJM 2021): 1,961 adults with overweight/obesity randomized to semaglutide 2.4 mg weekly vs placebo, 68 weeks. Mean body weight change: −14.9% on semaglutide vs −2.4% on placebo. STEP 5 (Garvey et al, 2023): 304 patients followed for 104 weeks — mean −15.2% maintained at 2 years on continuous 2.4 mg dosing.
At 2.4 mg, semaglutide maximally occupies GLP-1 receptors throughout the gut, pancreas, and central appetite-regulation circuitry. Gastric emptying slows by 80%+ in many patients. Appetite suppression is intense. Caloric intake typically drops 30-40% from pre-treatment baseline.
Reaching 2.4 mg: the titration path
| Weeks | Dose | Purpose |
|---|---|---|
| 1-4 | 0.25 mg | Starter / tolerance building |
| 5-8 | 0.5 mg | Second step |
| 9-12 | 1.0 mg | First therapeutic dose |
| 13-16 | 1.7 mg | Sub-max buffer step |
| 17+ | 2.4 mg | Target maintenance |
Side effect profile at 2.4 mg
From STEP 1 adverse event reporting: GI symptoms are most common — nausea 44.2%, diarrhea 31.5%, vomiting 24.8%, constipation 23.4%, abdominal pain 20.4%. Most are mild-to-moderate and decline over time. Severe AEs at 2.4 mg are uncommon but can require dose reduction or discontinuation. Pancreatitis is rare but possible — any sustained abdominal pain warrants clinician evaluation.
Get to 2.4 mg with Trimi
$99/month annual plan covers full titration from 0.25 mg starter to 2.4 mg maintenance. Same active ingredient as Wegovy.
Start your visitFAQs
Is 2.4 mg the maximum semaglutide dose?
Yes — 2.4 mg weekly is the FDA-approved maximum and target maintenance dose for Wegovy chronic weight management. There is no FDA-approved higher dose. Investigational semaglutide 7.2 mg is being studied (preliminary results published 2024-2025) but is not yet approved or available.
What weight loss does 2.4 mg produce?
STEP 1 NEJM 2021 trial: 14.9% mean body weight reduction at 68 weeks on Wegovy 2.4 mg vs 2.4% on placebo. STEP 5 (2-year follow-up): 15.2% maintained at 104 weeks. Per the trial protocol, 2.4 mg is the target maintenance dose patients reach after 16 weeks of titration (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg).
When do I reach 2.4 mg?
Week 17 per the standard titration. Wegovy and compounded semaglutide titration spends weeks 1-16 stepping up through 0.25 → 0.5 → 1.0 → 1.7 mg. At week 17, patients escalate to 2.4 mg and typically maintain at this dose for the duration of treatment.
Can I stay at 2.4 mg long-term?
Yes — that's the intended use. Wegovy is approved for chronic weight management as ongoing treatment. STEP 5 showed maintained weight loss at 2 years on 2.4 mg with continued GI tolerance for most patients. Real-world clinicians keep responding patients at 2.4 mg indefinitely as long as tolerance and outcomes remain good.
What side effects are common at 2.4 mg?
More frequent GI symptoms than lower doses: nausea (44% in STEP 1 vs 18% placebo), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%). Most are mild-to-moderate and decrease over time. Severe symptoms warrant either dropping back to 1.7 mg or pause/discontinuation per clinician guidance.
Should I escalate from 1.7 mg to 2.4 mg?
Depends on goals. If you're losing well at 1.7 mg and at/near goal weight, holding may be reasonable. If you've plateaued at 1.7 mg and want additional weight loss, escalating to 2.4 mg is the standard path. Trimi clinicians individualize this decision based on response, side effects, and goals.
What about 'Ozempic face' at 2.4 mg?
Risk is higher at 2.4 mg because rate of loss is faster than at sub-max doses. Patients concerned about facial volume loss can: (1) escalate to 2.4 mg but maintain extra protein and resistance training to preserve lean mass, (2) hold at 1.7 mg sub-max maintenance instead, or (3) escalate but slow loss rate via deliberate caloric intake management.
Related reading
Disclaimer: Informational, not medical advice. Trial citations: Wilding JPH et al, NEJM 2021 (STEP 1); Garvey WT et al, JAMA 2023 (STEP 5). Compounded semaglutide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug. Always consult a licensed clinician. **The FDA does not review or approve any compounded medications for safety or effectiveness.